{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:25:27Z","timestamp":1783689927933,"version":"3.55.0"},"reference-count":136,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007436","name":"Erling-Perssons Stiftelse","doi-asserted-by":"publisher","award":["2022_0030"],"award-info":[{"award-number":["2022_0030"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Myasthenia Gravis (MG) is a heterogeneous neuromuscular autoimmune disorder characterized by fluctuating skeletal muscle weakness and a highly variable disease course. MG subgroups are defined by antibody type, age at onset, clinical phenotype, and thymus pathology. Given the unpredictable disease course, disease-specific objective biomarkers are needed to enable personalized treatment strategies and improve clinical trial outcomes beyond conventional clinical scales. Biomarkers are measurable indicators of physiological processes, disease states, and therapy responses. Despite significant advances in MG diagnostics and therapeutics, predictive biomarkers for personalized treatment remain underdeveloped. This review explores the progress and challenges in identifying blood-based biomarkers for MG, highlighting their potential applications in diagnosis and disease monitoring. Established diagnostic blood biomarkers include autoantibodies against acetylcholine receptors (AChR) and muscle-specific tyrosine kinase (MuSK), which confirm MG diagnosis and guide initial treatment decisions. Prognostic biomarkers, such as microRNAs (miR-150-5p and miR-30e-5p), show promise in predicting disease progression. Pharmacodynamic biomarkers, including CD20+ B cell counts, may enhance treatment precision for therapies like Rituximab. Furthermore, emerging research on metabolites, T and B-cell markers, complement factors, and proteomics offer new avenues to refine MG subtyping and identify molecular signatures predictive of treatment response to novel immunosuppressants. While the journey toward clinically useful blood biomarkers in MG remains complex, ongoing collaborative efforts within the MG research community hold the potential to revolutionize disease management. Future studies integrating multi-omics approaches, large-scale longitudinal cohorts, and disease controls will be critical to translating these biomarkers from research into routine clinical practice.<\/jats:p>","DOI":"10.1177\/22143602251348753","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T10:34:37Z","timestamp":1750847677000},"page":"493-506","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["On the road to blood biomarkers in myasthenia gravis (MG): Beyond clinical scales"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0939","authenticated-orcid":false,"given":"Amol K","family":"Bhandage","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2617-2083","authenticated-orcid":false,"given":"Yu-Fang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-367X","authenticated-orcid":false,"given":"Tanel","family":"Punga","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-9413","authenticated-orcid":false,"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden"},{"name":"Clinical Neurophysiology, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008903"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22006"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.007"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103669"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110564"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091286"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302705"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203"},{"key":"e_1_3_3_11_2","first-page":"740583","article-title":"Three types of striational antibodies in myasthenia gravis","volume":"2011","author":"Suzuki S","year":"2011","unstructured":"Suzuki S, Utsugisawa K, Nagane Y, et al. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011; 2011; 740583.","journal-title":"Autoimmune Dis"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.11.1596"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135378"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(00)00394-5"},{"key":"e_1_3_3_16_2","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal","author":"Meisel A","year":"2022","unstructured":"Meisel A, Baggi F, Behin A, et al. Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal. Eur J Neurol 2022. doi:https:\/\/doi.org\/10.1111\/ene.15565","journal-title":"Eur J Neurol"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02754-6"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3158"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02299-y"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.10.001"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.05.004"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112275"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106130"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00809"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-918"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2012.02703.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.09.001"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3009-3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2021.11.020"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500725"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2016.07.049"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-8985-1"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901176"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000945"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.03.003"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9685-0"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.09.012"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04965-7"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001087"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000077"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00043"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.645"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.10.012"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000529626"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00916-w"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1439899"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110499"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13591"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071218"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2017.04.012"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11676"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-022-00501-8"},{"key":"e_1_3_3_55_2","article-title":"Altered serum levels of cytokines in patients with myasthenia gravis","volume":"10","author":"Wei SL","year":"2024","unstructured":"Wei SL, Yang CL, Si WY, et al. Altered serum levels of cytokines in patients with myasthenia gravis. Heliyon 2024; 10. doi:https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23745","journal-title":"Heliyon"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-015-9638-5"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577634"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-015-0358-1"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2019.009"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578205"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02729.x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12272"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.893458"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12057"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22070"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.06.011"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep25886"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-013-1460-3"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-020-09164-2"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2015.0367"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.09.010"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.11.017"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6036-7"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01885-z"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.54029\/2024kzf"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25162"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26590"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2383"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156485"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1159\/000322737"},{"key":"e_1_3_3_81_2","first-page":"151258","article-title":"Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls","volume":"2011","author":"Luckman SP","year":"2011","unstructured":"Luckman SP, Gilhus NE, Romi F. Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls. Autoimmune Dis 2011; 2011: 151258.","journal-title":"Autoimmune Dis"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12111439"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep39716"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1056322"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100111"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000831"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.01.004"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9646209"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4695(20000905)44:3<369::AID-NEU7>3.0.CO;2-Z"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEUR.0000020631.69804.f5"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706438104"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2022.10.017"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.5606\/tgkdc.dergisi.2023.24588"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18546"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S449324"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47559-x"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97599-8"},{"key":"e_1_3_3_98_2","first-page":"851","article-title":"Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis","volume":"70","author":"Huang YF","year":"2024","unstructured":"Huang YF, Sandholm K, Persson B, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle and Nerve 2024; 70: 851\u2013861. https:\/\/doi.org\/10.1002\/mus.28227","journal-title":"Muscle and Nerve"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02147-5"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02237"},{"key":"e_1_3_3_101_2","doi-asserted-by":"crossref","unstructured":"Barohn RJ Brey RL. Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg 1993; 285\u2013290.","DOI":"10.1016\/0303-8467(93)90103-N"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15730"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061360"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27973"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14500"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.24"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.06.019"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.05.003"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040740"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091927"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9595718"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00142"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2016.01.003"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2013.09.014"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12293"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.06.012"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9834-5"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00539"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.12.009"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2012.07.003"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3611"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.05.001"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.40"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-023-00611-y"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.10.003"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.692"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28177"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.24"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00539"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2023.9526"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2150566"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26785"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-019-1625-z"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-019-1571-9"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-011-0364-6"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102635"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287654"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251348753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602251348753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251348753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:59:18Z","timestamp":1780549158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602251348753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/22143602251348753"],"URL":"https:\/\/doi.org\/10.1177\/22143602251348753","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}